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Abstract 
Background: Patients diagnosed with triple negative breast cancer (TNBC) have limited treatment options and often 
suffer from resistance and toxicity due to chemotherapy. We previously found that depleting calcium and integrin-
binding protein 1 (CIB1) induces cell death selectively in TNBC cells, while sparing normal cells. Therefore, we asked 
whether CIB1 depletion further enhances tumor-specific killing when combined with either the commonly used 
chemotherapeutic, docetaxel, or the cell death-inducing ligand, TRAIL.
Methods: We targeted CIB1 by RNA interference in MDA-MB-436, MDA-MB-231, MDA-MB-468, docetaxel-resistant 
MDA-MB-436 TNBC cells and ME16C normal breast epithelial cells alone or combination with docetaxel or TRAIL. Cell 
death was quantified via trypan blue exclusion using flow cytometry and cell death mechanisms were analyzed by 
Western blotting. Cell surface levels of TRAIL receptors were measured by flow cytometry analysis.
Results: CIB1 depletion combined with docetaxel significantly enhanced tumor-specific cell death relative to each 
treatment alone. The enhanced cell death strongly correlated with caspase-8 activation, a hallmark of death receptor-
mediated apoptosis. The death receptor TRAIL-R2 was upregulated in response to CIB1 depletion, which sensitized 
TNBC cells to the ligand TRAIL, resulting in a synergistic increase in cell death. In addition to death receptor-mediated 
apoptosis, both combination treatments activated a non-apoptotic mechanism, called paraptosis. Interestingly, these 
combination treatments also induced nearly complete death of docetaxel-resistant MDA-MB-436 cells, again via 
apoptosis and paraptosis. In contrast, neither combination treatment induced cell death in normal ME16C cells.
Conclusion: Novel combinations of CIB1 depletion with docetaxel or TRAIL selectively enhance naive and docetaxel-
resistant TNBC cell death while sparing normal cell. Therefore, combination therapies that target CIB1 could prove to 
be a safe and durable strategy for treatment of TNBC and potentially other cancers.
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Background
Approximately 15–20% of all breast cancer deaths in the 
U.S. occur in patients diagnosed with triple-negative 
breast cancer (TNBC), a subtype defined by a lack of the 
estrogen receptor, progesterone receptor, and human 
epidermal growth factor receptor 2 (Ref. [1]). Due to 
lack of these targetable cell surface receptors, radiation, 
surgery, and chemotherapy remain the current standard 
of care [1, 2]. While a subset of TNBC patients respond 
initially to chemotherapy, they often suffer from toxicity 
and acquired resistance, resulting in cancer recurrence 
and metastasis [2–4]. Therefore, there is a critical need 
for efficacious therapies that limit toxicity and overcome 
resistance for TNBC patients.
Recent efforts to improve clinical efficacy of chemo-
therapies have shifted towards combining them with 
targeted approaches to lower effective chemotherapeu-
tic doses while maintaining therapeutic response [1, 2]. 
For instance, in clinical trials that targeted the epider-
mal growth factor receptor (EGFR), which is commonly 
upregulated/activated in TNBC, there was no improve-
ment in chemotherapeutic efficacy [5–7]. Moreover, 
while ongoing clinical trials are testing PI3K–AKT and 
MEK–ERK signaling pathways downstream of EGFR, 
toxicity remains unresolved with a modest to no increase 
in patient survival (NCT02423603, NCT01964924).
Our lab previously found that calcium and integrin-
binding protein 1 (CIB1), an intracellular protein that 
regulates highly oncogenic PI3K–AKT and MEK–ERK 
signaling, may represent a viable target in TNBC [8, 9]. 
We showed that CIB1 depletion simultaneously inhib-
its AKT and ERK activation and induces significant cell 
death in approximately 70% of TNBC cell lines tested 
and in an in vivo xenograft model [8]. Common to TNBC 
cell lines that are sensitive to CIB1 depletion is elevated 
AKT activation. Thus, CIB1 depletion does not cause 
cell death in TNBC and normal cell lines that exhibit low 
basal AKT activity [8]. Here, we evaluated cell death in 
TNBC versus normal breast epithelial cell lines using 
novel combination treatments involving CIB1 depletion 
with and without the commonly used chemotherapeu-
tic docetaxel. We found that CIB1 depletion enhanced 
docetaxel-induced cell death selectively in TNBC over 
normal cells largely via a death receptor-mediated, as 
opposed to mitochondrial-mediated apoptosis.
TNF-related apoptosis-inducing ligand (TRAIL), a 
death receptor ligand, was once thought to be a prom-
ising anti-cancer agent because of its selectivity for 
killing tumor but not normal cells; however, it was not 
pursued due to innate or acquired resistance driven 
by dysfunctional TRAIL receptors [10, 11]. Interest-
ingly, there is a growing interest in combining chemo-
therapeutic drugs or targeted approaches with TRAIL 
to overcome this resistance [12–14]. Here we find that 
CIB1 depletion in combination with the death receptor 
ligand TRAIL potentiates TNBC-selective cell death, 
likely due to the upregulation of TRAIL receptor-2 
(TRAIL-R2/DR5) in CIB1-depleted TNBC cells. Thus, 
TRAIL in combination with CIB1 depletion may rep-
resent a novel mechanism to sensitize TRAIL-resistant 
TNBC cells.
Chemotherapy not only causes toxicity, but also 
often leads to cancer recurrence [3]. Since recurrence 
driven by drug resistance is often associated with dys-
functional apoptotic mechanisms [15], one approach 
to circumvent resistance is to induce non-apoptotic 
cell death [4, 16]. Here, we identified paraptosis as a 
likely non-apoptotic mode of cell death induced by 
CIB1 depletion, due to the observed cellular swelling 
and intracellular vacuolization that are morphological 
hallmarks of paraptosis [17, 18]. Currently, there are no 
well-defined molecular mechanisms known to regulate 
paraptosis. However, the intracellular protein ALG-
2-interacting protein X (Alix) has been shown to inhibit 
paraptosis by preventing cytoplasmic vacuolization, 
potentially by regulating endosomal sorting and fusion 
with other organelles [17, 19]. Separate studies showed 
that known inducers of paraptosis such as withaferin 
A and reactive oxygen species decrease the expression 
of Alix in breast cancer cells [18, 20]. Therefore, loss 
of Alix expression is considered a molecular marker of 
paraptosis [17, 18, 20, 21]. In addition to downregula-
tion of Alix, insulin-like growth factor I receptor (IGF-
1R) tyrosine kinase and JNK activity were found to 
induce paraptosis [17]. Here we report that CIB1 deple-
tion alone or in combination with docetaxel/TRAIL not 
only restores apoptotic signaling but also induces par-
aptosis in docetaxel-resistant TNBC cells. Combination 
therapies involving CIB1 targeting could therefore pro-
vide safe and durable strategies for treatment of TNBC 
and potentially other cancers.
Materials and methods
Cell lines
The human triple-negative breast cancer cell lines 
(MDA-MB-436 [Perou Lab, UNC], MDA-MB-468 [UNC 
Lineberger Tissue Culture Facility], and MDA-MB-231 
(Otey Lab, UNC) were cultured in Dulbecco’s modified 
eagle medium (DMEM, Gibco) supplemented with 10% 
fetal bovine serum (Gemini) and 1% MEM non-essential 
amino acids (Gibco), with the addition of 10 μg/ml insu-
lin for MDA-MB-436 cells. The human normal breast 
epithelial cell line (ME16C, Perou lab) was cultured in 
MEBM (Lonza). All cells were maintained at 37  °C in a 
humidified atmosphere of 5%  CO2.
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Generation of docetaxel‑resistant MDA‑MB‑436 TNBC cell 
line
Docetaxel-resistant MDA-MB-436 cells (MDA-436-
DCXR) were established by culturing in growth media 
supplemented with increasing concentrations of doc-
etaxel (5 nM to 50 nM) over a 9-month period. Cells at 
approximately 40–50% confluency were incubated with a 
selected concentration for 48  h followed by recovery in 
drug-free growth media. The concentration of docetaxel 
was incrementally increased until the cells were resist-
ant, at a final concentration of 50 nM docetaxel (MDA-
436-DCXR). Parental MDA-MB-436 cells (MDA-436-PR) 
were cultured and passaged in parallel in drug-free 
growth media to control for extended time in culture.
Reagents
Docetaxel (Tocris), recombinant TRAIL (PeproTech), 
z-VAD-fmk (Enzo Life Sciences), TRAIL-R2 (DR5) 
neutralizing antibody (R&D system), and human con-
trol IgG (Jackson Immuno Research) were used to treat 
the cell lines.
CIB1 targeting via RNA interference in the absence 
and presence of docetaxel or TRAIL
Construction of control and CIB1 shRNA lentiviral 
plasmids has been described previously [8, 9]. Two 
different CIB1 targeting sequences (shCIB1-1 and 
shCIB1-2) were used to validate shRNA-induced CIB1 
depletion. To knock down CIB1, cells of interest at 
~ 30% confluence were infected with lentiviral shRNA 
containing 6 µg/ml polybrene (Sigma) for 16–18 h fol-
lowed by replacement with fresh growth media. After 
24 h, the shRNA-infected cells were treated with vehi-
cle, docetaxel, or TRAIL for an additional 48 h. Treated 
cells were then harvested 4  days post-infection, dur-
ing which time transduction efficiency exceeds 90% as 
determined by GFP fluorescence.
Trypan blue exclusion assay
Cell death was determined by trypan blue exclusion using 
automated fluorescently activated cell sorting (FACS) 
counting. Aliquots of 10 μl of both adherent and floating 
cell populations were collected and stained with 0.004% 
trypan blue (1:10 dilution). Stained dead cells were 
selected and counted using the Per-CP (APC) channel 
[22]. Quantification of total live and dead cell populations 
was determined using an Accuri C6 Flow Cytometer (BD 
Biosciences) and data are presented as percent cell death.
TRAIL‑R1 and ‑R2 fluorescence detection
To detect surface expression of TRAIL-R1 and -R2, 
2 × 105 cells were detached using 2 mM EDTA, washed 
in PBS, and resuspended in PBS (0.1% BSA) contain-
ing antibodies for TRAIL-R1/DR4, TRAIL-R2/DR5 
(eBiosciences) or IgG control. AlexaFluor 647 (Invitro-
gen) secondary antibody was used to detect the levels 
of TRAIL-R1/2, and mean fluorescence intensity was 
measured via Accuri C6 Flow Cytometer.
Western blotting
Cells were harvested and lysed with buffer contain-
ing 10  mM CHAPS as previously described [8]. Equal 
amounts of protein based on total cell number were sepa-
rated by SDS-PAGE, transferred to PVDF membrane, 
and incubated with primary antibodies overnight at 
4 °C. Secondary HRP-conjugated antibodies against rab-
bit, mouse, and chicken were then used to visualize the 
immunoblots via enhanced chemiluminescence (ECL2, 
Pierce). The following antibodies were used in this study: 
PARP, GAPDH, cleaved caspase-8, caspase-8, cleaved 
caspase-9, caspase-9, TRAIL-1/DR4, TRAIL-R2/DR5, 
IGF-1R, phospho-JNK, and total JNK (Cell Signaling), 
CIB1 (chicken polyclonal antibody, [9]), vinculin (Sigma), 
Alix (Biolegend).
Mitochondrial membrane potential detection
To detect changes in mitochondrial membrane potential, 
cells were stained with JC-1 (Thermofisher), a cationic 
dye that accumulates in the mitochondria. Cells (1 × 106) 
were dissociated and incubated in PBS containing JC-1 
(5  µM) for 30  min at 37  °C. JC-1 accumulates in func-
tional mitochondria to form aggregates that fluoresce 
red. In dysfunctional mitochondria with decreased mem-
brane potential, JC-1 will instead remain as monomers 
that fluoresce green. After washing with PBS, the emis-
sion of JC-1 fluorescence was analyzed using an Accuri 
C6 Flow Cytometer and associated software (BD Bio-
sciences). Therefore, calculation of red:green JC-1 fluo-
rescence ratio was used as the surrogate for changes in 
mitochondrial membrane potential.
Microscopy imaging
To assess morphological changes induced by CIB1 deple-
tion in the absence and presence of docetaxel or TRAIL, 
cells were imaged in 6-well plates at the conclusion of 
each experiment. Differential interference contrast (DIC) 
images were captured using a Nikon TE300 microscope 
equipped with an Andor Zyla sCMOS camera (20x 
objective).
Statistics
The statistically significant differences were determined 
using either a one-way ANOVA or student’s two-tailed 
t-test. More details on p-values are indicated in the figure 
legends.
Page 4 of 15Chung et al. Cancer Cell Int           (2019) 19:26 
Results
CIB1 depletion selectively enhances docetaxel‑induced 
TNBC cell death
We previously reported that CIB1 depletion leads to 
TNBC cell death while sparing normal cells [8], sug-
gesting that CIB1 may be a viable, safe target. To 
address the need to enhance tumor cell death and 
maintain tolerability by normal cells, we tested the tar-
geting of CIB1 via RNA interference in combination 
with the commonly used chemotherapeutic agent, doc-
etaxel, in both TNBC and a normal breast epithelial cell 
line. Two different CIB1 shRNA sequences (shCIB1-1 
and shCIB1-2) were used to validate CIB1 depletion 
(Additional file 2: Figure S1A). CIB1 depletion-induced 
cell death quantification, cell death signaling, and cellu-
lar morphology were also validated using both shRNA 
sequences (Additional file 2: Figure S1B–H) and West-
ern blots were quantified in Additional file 1: Table S1. 
Since similar results were observed with both shRNA 
sequences, we chose CIB1 shRNA-1 for the remainder 
of the experiments.
To test whether the combination of CIB1 depletion 
and docetaxel enhances cell death, we selected three 
different TNBC cell lines based on their sensitivity 
to CIB1 depletion-MDA-MB-436 (sensitive, Fig.  1a), 
MDA-MB-468 (sensitive, Fig.  1b), and MDA-MB-231 
(insensitive, Fig.  1c) [8]. Dosages of docetaxel that 
caused 30–50% TNBC cell death were chosen to be 
combined with CIB1 depletion (Fig. 1). We found that 
CIB1 depletion enhanced docetaxel-induced cell death 
more effectively in CIB1 depletion-sensitive (Fig. 1a, b) 
versus insensitive cells (Fig.  1c). The enhanced TNBC 
MDA-MB-436 cell death was indistinguishable with 
either shCIB1-1 or -2 alone or combined with docetaxel 
(Additional file 2: Figure S1B). In contrast, CIB1 deple-
tion alone or in combination with docetaxel did not sig-
nificantly increase cell death in normal breast epithelial 
ME16C cells (Fig.  1d), suggesting that CIB1 targeting 
may improve chemotherapeutic efficacy by tumor-
selective killing.
To elucidate the mechanism underlying the enhanced 
TNBC cell death induced by CIB1 depletion plus doc-
etaxel (Fig.  1a–c), we analyzed cell lysates for cleaved 
PARP, a marker of apoptosis. In agreement with the 
observed enhanced cell death, the combined treatment-
induced PARP cleavage was only observed in TNBC 
(Fig. 1a–c) but not normal breast epithelial ME16C cells 
(Fig.  1d). CIB1 knockdown was confirmed by Western 
blotting (Fig. 1a–d). Collectively, our results indicate that 
the novel combination of CIB1 depletion and docetaxel 
selectively enhances TNBC cell death via increased apop-
totic signaling.
CIB1 depletion with docetaxel induces death 
receptor‑mediated apoptosis
To further understand the apoptotic signaling mecha-
nisms induced by CIB1 depletion in combination with 
docetaxel, we asked whether death receptor-mediated or 
mitochondrial apoptosis, which are initiated by caspase-8 
and caspase-9, respectively, contributed to the observed 
cell death. We detected degradation of inactive pro-cas-
pase-8 and the appearance of active or cleaved caspase-8, 
but not caspase-9, in CIB1-depleted cells treated with 
docetaxel (Fig.  2a and Additional file  2: Figure S1C). In 
contrast, we detected minimal caspase-8 activity in CIB1-
depleted cells alone (Fig. 2a and Additional file 2: Figure 
S1C), suggesting that CIB1 depletion may prime TNBC 
cells for death receptor-mediated apoptosis. Comparable 
effects on apoptotic signaling induced by CIB1 depletion 
alone or with docetaxel was also observed using CIB1 
shRNA-2 (Additional file 2: Figure S1C). We additionally 
probed for caspase-10, a controversial marker of death 
receptor-mediated apoptosis [23], and found no further 
caspase-10 activation upon combination treatments (data 
not shown). Caspase-3, a downstream substrate of cas-
pase-8, was also activated by the combination treatment 
(Fig. 2a). In contrast, we did not observe caspase activa-
tion in control or CIB1-depleted ME16C normal breast 
epithelial cells with or without docetaxel (Fig. 2b). CIB1 
depletion in combination with docetaxel also selectively 
activated caspase-8 in two additional TNBC cell lines, 
MDA-468 (Additional file 3: Figure S2A) and MDA-231 
cells (Additional file  3: Figure S2B). Collectively, these 
results suggest that death receptor-mediated apoptotic 
signaling contributes mechanistically to enhanced cell 
death induced by the combination of CIB1 depletion and 
docetaxel selectively in TNBC cells, regardless of their 
sensitivity to CIB1 depletion.
CIB1 depletion sensitizes TNBC, but not normal cells 
to TRAIL
Since CIB1 depletion enhances docetaxel-induced TNBC 
cell death via increased death receptor signaling, we 
investigated the link between CIB1 depletion and two 
cytotoxic death receptors, TRAIL (TRAIL-R) and Fas. 
Treatment of CIB1-depleted MDA-436 cells with Fas 
ligand had no effect on cell death or caspase-8 activa-
tion (data not shown), and therefore was not pursued 
further. However, treatment with TRAIL caused a dose-
dependent increase in PARP cleavage (Fig. 3a). Notably, 
CIB1 depletion sensitized MDA-436 cells to TRAIL, 
resulting in a synergistic increase in cell death (Fig.  3a 
and Additional file  2: Figure S1D). In contrast, CIB1 
depletion plus TRAIL failed to induce PARP cleavage 
and cell death in normal ME16C cells (Fig. 3b), indicating 
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that this combination is highly selective in killing TNBC 
while sparing normal cells. Further, the enhanced cell 
death correlated with active or cleaved caspase-3 and 
caspase-8, but not caspase-9, in CIB1 shRNA-1 and 
shRNA-2 depleted MDA-436 TNBC cells (Fig.  3c and 
Additional file 2: Figure S1E) not ME16C cells (Fig. 3d). 
Caspase-8 activation was also confirmed by the corre-
sponding degradation of inactive pro-caspase-8 (Fig. 3c). 
Although we did not detect caspase-9 activation (Fig. 3c), 
staining with the mitochondrial dye JC-1 revealed 
Fig. 1 CIB1 depletion in combination with docetaxel enhances cell death and increases caspase activation in TNBC but not normal ME16C cells. 
Combination of CIB1 depletion with docetaxel in both TNBC and normal cells was tested. Cells were infected with control or CIB1 shRNA for 2 days 
before addition of vehicle (DMSO) or the indicated concentrations of docetaxel for 48 h. Percent cell death in a MDA-436 TNBC (n = 5), b MDA-468 
TNBC (n = 3), c MDA-231 TNBC (n = 3), and d ME16C normal breast epithelial cells (n = 4) was quantified via a trypan blue exclusion assay from both 
adherent and floating cell populations. Lysates prepared from cells in a–d [n = 5; 3; 3; 4, respectively] were analyzed by Western blotting with the 
indicated antibodies (lower panels). Data represent mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, ANOVA)
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increased mitochondrial dysfunction in CIB1-depleted 
cells alone and in combination with both TRAIL and 
docetaxel (Additional file 4: Figure S3A). Caspase-8 can 
cleave the pro-apoptotic Bcl-2 member, Bid, which is an 
important mediator of mitochondrial dysfunction [24]. 
Consistent with our JC-1 results, we detected increased 
Bid cleavage in CIB1 depleted cells treated with either 
docetaxel or TRAIL (Additional file  4: Figure S3B, C), 
further suggesting apoptotic cell death.
Interestingly, we also observed a similar increase in cas-
pase-8 activation and cell death upon addition of TRAIL 
to CIB1-depleted MDA-468 (Additional file  5: Figure 
S4A) but not MDA-231 TNBC cells (Additional file  5: 
Figure S4B). This suggests that the cell death induced by 
the combination of CIB1 depletion and TRAIL, unlike 
that induced by docetaxel, is cell-type specific based on 
sensitivity to CIB1 depletion. Thus, adding TRAIL to 
CIB1 depletion-sensitive cells is a potent combination for 
inducing caspase-8 activation and cell death.
TRAIL‑R2 upregulation by CIB1 depletion sensitizes TNBC 
cells to TRAIL
Because CIB1 depletion sensitizes TNBC cells to TRAIL, 
we asked whether this effect was due to increased 
TRAIL-R expression. We measured cell-surface and 
whole cell expression of TRAIL-R1 (DR4) and/or 
-R2 (DR5) using flow cytometry and Western blot-
ting, respectively. We found that TRAIL-R2, but not 
TRAIL-R1, was upregulated on the surface of CIB1-
depleted versus control MDA-436 TNBC cells, start-
ing 2  days post-infection with both CIB1-1 and CIB1-2 
shRNA sequences (Fig.  4a, b; Additional file  2: Figure 
S1F, G). This was notable because TRAIL was added 
2 days post-infection and coincides with acquired sensi-
tivity to TRAIL. Whole cell expression levels of TRAIL-
R2 also increased with CIB1 depletion starting at Day 2, 
but more significantly at Day 3 post-infection (Fig.  4c). 
Next, to confirm that TRAIL-R2 upregulation upon CIB1 
depletion was responsible for sensitizing MDA-436 cells 
to TRAIL, we blocked TRAIL-R2 function by pre-treat-
ing control or CIB1-depleted MDA-436 TNBC cells with 
a neutralizing (TRAIL-R2 Fc) antibody. Blocking TRAIL-
R2 prevented the increased cell death induced by TRAIL 
in CIB1-depleted cells (Fig.  4d). Further, this rescue of 
cell viability by the TRAIL-R2 neutralizing antibody was 
also associated with decreased PARP cleavage and cas-
pase-8-activation, whereas the upregulation of TRAIL-
R2 by CIB1 depletion remained intact (Fig.  4e). These 
results indicate that CIB1 depletion-induced TRAIL-R2 
upregulation sensitizes TNBC cells to TRAIL.
CIB1 depletion plus docetaxel or TRAIL induces 
caspase‑independent cell death
To confirm apoptosis as the primary mechanism under-
lying the observed death of CIB1-depleted MDA-436 
TNBC cells with or without docetaxel/TRAIL, we 
Fig. 2 CIB1 depletion combined with docetaxel enhances death receptor-mediated apoptotic signaling. Docetaxel-induced caspase-8 and -3 
activation is enhanced in CIB1-depleted MDA-436 but not normal ME16C cells. Control or CIB1-depleted a MDA-436 TNBC (n = 5) and b ME16C 
normal breast epithelial cells (n = 4) were treated with docetaxel as in Fig. 1. Lysates prepared from each cell line were probed for pro-caspase-8, 
cleaved caspase-8, pro-caspase-9, cleaved caspase-9, cleaved caspase-3, CIB1, and vinculin (loading control)
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pre-treated cells with the pan-caspase inhibitor, z-VAD-
fmk (z-VAD). Surprisingly, we found that z-VAD par-
tially rescued MDA-436 cell viability induced by CIB1 
depletion in combination with either docetaxel (Fig. 5a) 
or TRAIL (Fig.  5b) despite complete inhibition of cas-
pase-8 and caspase-3 activation (Fig.  5c, d). These 
results led us to investigate the contribution of caspase-
independent cell death mechanisms. Phenotypically, we 
noticed that CIB1 depletion alone induced cellular swell-
ing and intracellular vacuolization (Additional file  2: 
Figure S1H), which are characteristic of autophagic, 
necroptotic, or paraptotic modes of caspase-independ-
ent non-apoptotic cell death [16, 17, 25]. After detect-
ing no changes in LC-III and p-RIPK1 levels, markers 
of autophagy and necroptosis, respectively (data not 
shown), those modes of cell death seemed less likely. 
Fig. 3 CIB1 depletion sensitizes MDA-436 TNBC but not normal ME16C cells to TRAIL. Combination of CIB1 depletion with TRAIL in both TNBC 
and normal cells was tested. Cells were infected with control or CIB1 shRNA for 2 days before the addition of vehicle (water) or the indicated 
concentrations of a death receptor ligand TRAIL for 48 h. Percent cell death quantified via trypan blue exclusion using a MDA-436 TNBC (n = 4) 
and b ME16C normal breast epithelial cell lines (n = 3). Data represent mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, ANOVA). 
CIB1 depletion plus TRAIL enhanced caspase-8 and -3 activation. Representative Western blot for pro-caspase-8, cleaved caspase-8, pro-caspase-9, 
cleaved caspase-9, cleaved caspase-3, CIB1, and vinculin in c MDA-436 TNBC (n = 3) and d ME16C cells (n = 3)
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Fig. 4 CIB1 depletion upregulates TRAIL-R2 expression Death receptors TRAIL-R1/R2 levels in MDA-436 cells were measured at Days 2, 3, and 4 
post-infection with either control or CIB1 shRNA. a FACS analysis shows upregulation of cell surface levels of TRAIL-R2, but not TRAIL-R1, starting at 
2, 3 and 4 days post-infection (2nd and 3rd row) with CIB1 shRNA (red) relative to control (black). b Mean ± SD (n = 3) of fluorescence intensities 
of CIB1 shRNA-infected MDA-436 cells normalized to control cells shown in a. c Representative western blot (n = 3) showing increased whole cell 
expression of TRAIL-R2, but not TRAIL-R1, in CIB1-depleted MDA-436 cells at 3 and 4 days post-infection with CIB1 shRNA. d TRAIL-R2 neutralizing 
antibody blocks TRAIL-induced cell death in CIB1-depleted cells. Control or CIB1-depleted MDA-436 cells were pre-treated with either IgG control 
or TRAIL-R2 neutralizing antibody (TRAIL-R2 Fc, 1 ng/ml) for 24 h before addition of vehicle (water) or 10 ng/ml recombinant TRAIL ligand for 48 h 
(n = 3). Cell death was quantified as in Fig. 1 (**P < 0.01). e Blocking TRAIL-R2 inhibits TRAIL-induced PARP cleavage and caspase-8 activation in 
CIB1-depleted MDA-436 cells. Representative Western blot of PARP, TRAIL-R2, cleaved caspase-8, CIB1, and GAPDH (loading control) in treatment 
groups shown in d) (n = 3)
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We then assessed ALG-2-interacting protein X (Alix) 
protein expression levels, which correlate inversely with 
induction of paraptosis [17, 18]. We detected decreased 
Alix expression upon CIB1 depletion in combination 
with either docetaxel (Fig. 5c) or TRAIL (Fig. 5d) (0.3- or 
0.08-fold respectively). Even with z-VAD pre-treatment, 
we detected decreased Alix expression in response to 
CIB1 depletion plus docetaxel or TRAIL (0.6- or 0.7-
fold respectively, Fig.  5c, d), suggesting paraptosis as a 
non-apoptotic component of cell death. Because parap-
tosis can also be mediated by IGF-1R signaling and JNK 
activation [17] we probed for IGF-1R expression and 
phospho-JNK. We found that CIB1 depletion alone led 
to increased IGF-1R expression, and the combination 
treatment activated JNK signaling, further supporting the 
involvement of paraptosis (Additional file 6: Figure S5A). 
Although not a specific inhibitor of paraptosis (protein 
synthesis inhibitor), pre-treatment using cycloheximide 
rescued CIB1 depleted TNBC cells (Additional file  6: 
Figure S5B). These findings suggest that CIB1 depletion 
combined with docetaxel or TRAIL induces paraptosis.
Docetaxel‑resistant TNBC cells remain sensitive to CIB1 
depletion alone or in combination with docetaxel or TRAIL
Defective apoptosis is one mechanism of resistance and a 
major obstacle for effective chemotherapy [15]. Therefore, 
Fig. 5 CIB1 depletion in combination with docetaxel or TRAIL induces caspase-independent cell death. Pre-treatment using a pan-caspase 
inhibitor, z-VAD-fmk (z-VAD) helped to determine contributions of caspase-independent, non-apoptotic cell death mechanisms induced by the 
combination treatments. Control or CIB1-depleted cells were pretreated with vehicle (DMSO) or 50 µM z-VAD-fmk (z-VAD) for 24 h before adding a 
10 nM docetaxel or b 10 ng/ml TRAIL for 48 h. The concentrations for docetaxel and TRAIL were chosen because we observed a sufficient increase 
in cell death and caspase-8 activity when combined with CIB1 depletion. Percent cell death was quantified as in Fig. 1, represented by mean ± SD, 
*P < 0.05 (n = 3). z-VAD inhibits caspase-8 but does not affect PARP activation or the expression of a marker of paraptosis, Alix. Lysates prepared from 
control or CIB1-depleted cells in a and b treated with c docetaxel or d TRAIL were probed with for PARP, cleaved caspase-8, cleaved caspase-3, Alix, 
CIB1, and vinculin (loading control). Western blot is representative of 3 independent experiments
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we asked whether CIB1 depletion overcomes resistance 
by restoring apoptosis. To answer this question, we gen-
erated docetaxel-resistant MDA-MB-436 cells (MDA-
436-DCXR). Resistance was confirmed by comparing the 
 EC50 of docetaxel in parental (MDA-436-PR; 3 nM) ver-
sus resistant (MDA-436-DCXR; 219 nM) cells (Additional 
file 7: Figure S6A). CIB1 depletion alone or with docetaxel 
(Fig. 6a) or TRAIL (Fig. 6b) induced significant cell death 
in docetaxel-resistant MDA-436-DCXR cells. Western 
blotting analysis showed that although docetaxel-induced 
caspase-8 activity is compromised in MDA-436-DCXR 
resistant cells, CIB1 depletion alone and in combination 
with docetaxel restored caspase-8 activity in these cells 
(Fig. 6c). Contrary to previous findings, caspase-8 activ-
ity was not detected in CIB1-depleted MDA-436-PR 
parental cells with or without docetaxel/TRAIL (Fig. 6c). 
This may be due to alterations in caspase activities [26] 
resulting from extended culturing of MDA-436–PR cells 
during the process of establishing MDA-436-DCXR cells 
(> 9  months with > 60 passages). Unexpectedly, CIB1 
depletion plus TRAIL caused nearly complete death of 
MDA-436-DCXR cells (Fig.  6b), which may explain an 
apparent lack of GAPDH expression (Fig. 6c) due to the 
lysates being composed of mostly floating dead cells. The 
nearly complete MDA-436-DCXR cell death correlated 
with a more profound caspase-8 activation (Fig. 6c). This 
further amplification of caspase-8 activity could be due to 
increased cell surface expression of both TRAIL-R1 and 
-R2 on CIB1-depleted MDA-436-DCXR cells as opposed 
to only TRAIL-R2 in CIB1-depleted MDA-436-PR cells 
(Additional file  7: Figure S6B, C). Whole cell expres-
sion levels of TRAIL-R2 increased with CIB1 depletion 
in MDA-436-DCXR cells (Additional file 7: Figure S6D). 
These results suggest that CIB1 depletion alone and in 
combination with either docetaxel or TRAIL has the 
potential to overcome chemo-resistance.
Since another strategy to circumvent chemo-resist-
ance is to induce non-apoptotic, caspase-independent 
cell death [16], we asked whether paraptosis also occurs 
in docetaxel-resistant cells. Indeed, we found that either 
CIB1 depletion alone or in combination with docetaxel 
or TRAIL decreased Alix levels in MDA-436-DCXR 
cells (Fig.  6c). Moreover, paraptotic morphologies such 
as swelling and intracellular vacuole formation were 
observed in resistant cells in response to CIB1 depletion 
alone or in combination with docetaxel/TRAIL (Fig. 6d). 
The morphology of CIB1-depleted cells mimicked the 
effects of docetaxel (Fig.  6d), a parental compound to 
paclitaxel, which is known to cause paraptotic morphol-
ogy at high doses [27]. Although the combination treat-
ments did not activate the JNK pathway, CIB1 depletion 
alone led to upregulation of IGF-1R, an upstream effec-
tor of paraptosis, in docetaxel-resistant TNBC cells 
similar to that observed in parental cells (Additional 
file  7: Figure S6E). These results collectively show that 
the combination treatments both restore apoptosis and 
induce paraptosis as potential mechanisms to overcome 
chemo-resistance.
Discussion
The standard of care for TNBC patients, chemotherapy 
and/or surgery, often fails due to development of resist-
ance and toxicity [3, 28]. To address this need, clinical tri-
als have centered on combining targeted therapies with 
chemotherapeutics, yet resistance and toxicity persist 
to limit the overall efficacy [2, 4–6]. Our previous work 
indicated that CIB1 may be a potentially safe target due 
to its selectivity for killing TNBC but not normal cells 
when depleted [8]. Therefore, we tested a novel combi-
nation treatment with CIB1 depletion and a commonly 
used chemotherapeutic, docetaxel to enhance TNBC-
selective cell death.
In this study, we focused on detecting and understand-
ing the mechanisms of cell death to assess the combina-
tion of CIB1 depletion and chemotherapeutics. Many 
previous pre-clinical cell culture-based TNBC studies 
that combine targeted agents with chemotherapeutics 
have focused primarily on slowing cell proliferation as 
opposed to cell death [29–32]. Moreover, studies that 
have quantified cell death were often limited to studying 
classical caspase-dependent apoptosis [33–36]. In con-
trast, we investigated both apoptotic and non-apoptotic 
TNBC cell death in response to CIB1 depletion alone 
or in combination with docetaxel. In addition, we dem-
onstrate that induction of non-apoptotic cell death is an 
effective strategy to circumvent resistance, which is often 
(See figure on next page.)
Fig. 6 Docetaxel resistant MDA-436 cells are sensitive to CIB1 depletion alone and in combination with docetaxel or TRAIL. To determine whether 
chemo-resistance is overcome by the combination treatments, cell death and its mechanism were analyzed. Control or CIB1-depleted MDA-436-PR 
(parental) and MDA-436-DCXR (docetaxel-resistant) cells were treated with either a vehicle control (DMSO) or 10 nM docetaxel (n = 3), b or 5 ng/
ml TRAIL ligand (n = 3) for 48 h. Percent cell death shown in mean ± SD was quantified as in Fig. 1. c Western blots showing increased caspase-8 
activation and decreased Alix expression in CIB1-depleted MDA-436-DCXR cells alone or in combination with docetaxel or TRAIL, representative 
of 3 individual experiments. GAPDH was used as a loading control. d Representative DIC images (20×) of control or CIB1-depleted parental 
(MDA-436-PR) and MDA-436-DCXR cells treated with either vehicle or 10 nM docetaxel or 5 ng/ml. Insets show characteristics of paraptotic 
morphology in CIB1-depleted cells in the absence or presence of docetaxel/TRAIL
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associated with dysfunctional apoptotic signaling [16, 37, 
38]. Thus, we propose that quantification of cell death 
in tumor versus normal cells may identify combinations 
that eradicate tumors while sparing normal cells, which 
may be a better indicator for a safer, more efficacious 
therapy.
Initially, we found that combining CIB1 depletion with 
docetaxel significantly enhances TNBC cell death while 
sparing normal breast epithelial cells. The enhanced cell 
death correlated with increased death receptor-mediated 
(caspase-8) apoptotic signaling, selectively in TNBC 
relative to normal cells. Subsequently, we found that the 
combination of CIB1 depletion and the death receptor 
ligand TRAIL is potent in selectively killing TNBC cells 
via increased caspase-8 activation. While TNBC cells 
are inherently resistant to TRAIL alone, CIB1 depletion 
appears to sensitize these cells to TRAIL by upregulat-
ing TRAIL receptor-2. Once believed to be a safe, tumor-
specific targeting therapy, TRAIL as a mono-therapy 
failed due to resistance driven by mutations in TRAIL 
receptors and dysfunctional signaling complexes at the 
receptor intracellular domain [10, 11, 39]. Subsequent 
studies have focused on combination approaches using 
chemotherapeutics, natural compounds and targeted 
agents to sensitize otherwise resistant breast cancer cells 
to TRAIL by upregulating TRAIL receptors and restoring 
TRAIL receptors’ intracellular signaling complex activ-
ity [14, 40–45]. In comparison, our approach of targeting 
CIB1 allowed us to use five to tenfold lower concentra-
tions of TRAIL to induce as much or greater cytotoxicity 
in cultured TNBC cells. The selectivity of TRAIL-based 
combination treatments for tumor cells is consistent 
between our results and the published results of other 
studies [14, 43, 45]. However, those studies provide lim-
ited understanding as to why normal cells are unaffected 
by TRAIL-based combination treatments. We speculate 
that CIB1 depletion may upregulate decoy receptors, 
which inhibit intracellular TRAIL receptor signaling and 
initiate pro-survival NF-κB signaling [46, 47] (data not 
shown), thereby protecting normal breast epithelial cells 
from TRAIL-induced cell death. Another mechanism 
may involve the internalization of TRAIL receptors and 
expression of intracellular signaling complex modula-
tors such as c-FLIP, XIAP, and IAP in normal cells, to 
explain TNBC-selective cell death. We believe that a bet-
ter understanding of cell death mechanisms underlying 
tumor selectivity versus normal cells could provide fur-
ther rationale to test a TRAIL-based combination treat-
ment with CIB1 targeting.
The induction of non-apoptotic death could prove to 
be an effective therapeutic strategy to circumvent resist-
ance [16, 38, 48, 49]. In addition to previously identifying 
GAPDH nuclear translocation [9], we found paraptosis as 
another mode of non-apoptotic cell death associated with 
CIB1 depletion. To our knowledge, we are the first to 
report paraptosis as a mechanism for overcoming chem-
oresistance in TNBC cells. While autophagy is another 
mode of non-apoptotic cell death that shares phenotypic 
characteristics similar to paraptosis, we did not observe 
activation of LC-III, a marker of autophagy. Necropto-
sis, like apoptosis, can be activated downstream of death 
receptors to cause a caspase-independent paraptotic-like, 
necrotic phenotype [50]. However, we found no effect on 
the necrotic marker p-RIPK or the necroptosis inhibitor 
necrostatin-1 and therefore concluded that CIB1 deple-
tion alone or in combination with either docetaxel or 
TRAIL does not induce necroptosis. Because pre-treat-
ment with cycloheximide, a protein synthesis inhibitor, 
rescued CIB1 depleted TNBC cells from cell death, pro-
tein synthesis may be investigated to further understand 
non-apoptotic cell death in relation to CIB1. Future stud-
ies examining non-apoptotic modes of cell death associ-
ated with CIB1 targeting will provide additional insight 
into mechanisms to circumvent chemo-resistance.
Fig. 7 Model of cell death mechanisms induced by CIB1 depletion 
alone or in combination with docetaxel/TRAIL. The combination of 
CIB1 targeting via RNA interference and docetaxel/TRAIL activates 
both apoptotic and non-apoptotic (paraptotic) signaling to 
induce TNBC-selective cell death and overcome chemo-resistance. 
Caspase-3/-8 activation and decreased Alix levels were used as 
markers of apoptosis and paraptosis, respectively
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Conclusions
In summary, we find that targeting CIB1 in combination 
with docetaxel or TRAIL is selective in killing TNBC 
over normal breast epithelial cells. Also, both combina-
tions restore apoptosis and induce non-apoptotic cell 
death to overcome resistance (Fig. 7), suggesting well-tol-
erated and durable treatment options. Hence, we specu-
late that CIB1 as a target may provide new avenues for 
formulating effective combination therapies not only for 
TNBC but other cancers as well.
Additional files
Additional file 1: Table S1. Comprehensive quantification of cell death 
signaling levels by densitometry.
Additional file 2: Figure S1. Validation of CIB1 depletion alone or in com-
bination with docetaxel or TRAIL. MDA-436 TNBC cells were infected with 
either control or two different lentiviral CIB1 shRNA sequences (FG12 [1] 
and PLKO [2]). a) Western blot results followed by quantification via densi-
tometry show similar CIB1 knockdown and TRAIL-R2 upregulation in MDA-
436 cells infected with either CIB1 shRNA-1 or -2 for 96 h. Two days-post 
infection, cells were treated with vehicle control or, b) docetaxel (1 [n=5] 
and 2 [n=3]), or c) TRAIL (1 [n=3] and 2 [n=3]) for 48 h. Percent cell death 
was quantified via trypan blue exclusion assay and is shown as means +/- 
SD. Next, we examined death receptor-mediated apoptotic and paraptotic 
signaling induced by the combination treatment using CIB1 shRNA-1 or 
-2. Representative Western blot showing PARP, cleaved caspase-9, cleaved 
caspase-8, Alix, CIB1, and GAPDH in shControl (shCTRL) or shCIB1 (1 and 
2) infected cells in combination with d) docetaxel (1 [n=5] and 2 [n=3]) 
or e) TRAIL (1 [n=3] and 2 [n=3]). FACS analysis of f) TRAIL-R1 and g) 
-R2 cell surface expression in CIB1-depleted MDA-436 cells in relative to 
control cells at 2, 3, or 4 days post infection. Data represent means +/- SD 
(n=3). h) Representative DIC images (20x) of shControl (shCTRL), shCIB1-1, 
or shCIB1-2 MDA-436 TNBC cells. Insets show characteristic paraptotic 
morphology in CIB1-depleted cells (shCIB1) relative to control (shCTRL). 
**Please note that quantifications of cell death (Additional file 2: Figure 
S1B and S1D) and TRAIL-1/2 levels (Additional file 2: Figure S1F and S1G) 
using shCIB1-1 were taken from Figures 1, 2, 3, 4 solely to show side-by-
side comparisons with shCIB1-2.
Additional file 3: Figure S2. CIB1 depletion plus docetaxel or TRAIL acti-
vates Bid and disrupts mitochondrial membrane potential. Mitochondrial 
apoptosis was further investigated by probing for a pro-apoptotic Bcl-2 
related protein, Bid, and analyzing mitochondrial membrane potential by 
staining with JC-1. Control or CIB1-depleted MDA-436 cells were treated 
with docetaxel/TRAIL, followed by immunoblotting and JC-1 staining. 
Lysates from combination treatments involving a) docetaxel (n=2) and 
b) TRAIL (n=2) were probed for Bid and GAPDH (loading control using. 
c) Quantification of JC-1 aggregates (red) versus monomers (green) 
was used a surrogate for mitochondrial membrane potential. Data are 
represented in means +/- SD (n=3). p-value * <0.05; ** <0.01 compared 
to untreated control, two tailed t-test.
Additional file 4: Figure S3. CIB1 depletion plus docetaxel activates 
death receptor-mediated apoptosis in other TNBC cells. Caspase-8 
activation is observed in TNBC cell lines treated with the combination of 
CIB1 depletion and the indicated concentrations of docetaxel. Control 
and CIB1-depleted a) MDA-468 (n=3) and b) MDA-231 (n=3) cells were 
treated with either vehicle (DMSO) or docetaxel as in Additional file 2: 
Figure S1B. Representative Western blot showing cleaved caspase-8 and 
GAPDH (lower panel, n=3).
Additional file 5: Figure S4. CIB1 depletion plus TRAIL increases death 
receptor-mediated apoptosis in a CIB1 depletion-sensitive TNBC cells. CIB1 
depletion in combination with TRAIL induces cell death in CIB1-depletion 
sensitive but not insensitive TNBC cells. Control and CIB1-depleted a) 
MDA-468 and b) MDA-231 cells were treated with either vehicle (water) 
or TRAIL as in Additional file 2: Figure S1B. Percent cell death quantified 
as in Additional file 2: Figure S1 and is shown in means +/- SD (n=3) (*P 
< 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, ANOVA). Interestingly, 
increased caspase-8 activity in response to CIB1 depletion plus TRAIL was 
detected in both cells. Representative Western blots of 3 separate experi-
ments showing PARP, cleaved caspase-8, CIB1, and GAPDH expression 
(lower panel).
Additional file 6: Figure S5. Combination of CIB1 depletion and 
docetaxel/TRAIL induces paraptosis. Paraptotic signaling was funder 
investigated by analyzing IGF-1R and JNK pathways. a) Control or CIB1 
depleted MDA-436 cells were treated with either docetaxel (10 nM & 35 
nM) or TRAIL (5 ng/mL & 10 ng/mL) as described in Figure 1. Lysates were 
probed for IGF-1R, phosphorylated JNK, total JNK, and GAPDH (n=2). b) 
To determine the contribution of paraptotic cell death, control or CIB1-
depleted MDA-436 cells were pretreated with vehicle (DMSO) or 5 mM of 
the protein synthesis inhibitor cycloheximide for 24 h before adding 30 
nM docetaxel or 10 ng/ml TRAIL for 48 h. Percent cell death was quantified 
and normalized to control, represented by means +/- SD (n = 3).
Additional file 7: Figure S6. CIB1 depletion may upregulate TRAIL-R1/
R2 and IGF-1R expression in docetaxel-resistant TNBC cells. CIB1 depletion 
potentiates TRAIL-induced cell death in docetaxel-resistant MDA-436 
cells potentially via upregulation of both TRAIL-R1 and –R2. a) Dose-
response of docetaxel-induced cell death in parental (MDA-436-PR) 
versus docetaxel-resistant (MDA-436-DCXR) TNBC cells over 48 hr confirms 
resistance in MDA-436-DCXR cells. Cell death was quantified using trypan 
blue exclusion assay. Data represents means +/- SD (n=2). FACS analysis 
of cell surface expression of b) TRAIL-R1 and c) TRAIL-R2 in CIB1 depleted 
(shCIB1) MDA-436-PR and MDA-436-DCXR cells normalized to IgG-stained 
control cells (shCTRL) 4 days post infection with RNA interference. Data 
represent means +/- SD (n=3); * P < 0.05; ** P < 0.01. d) Representative 
Western blot from 3 separate experiments showing TRAIL-R1, TRAIL-R2, 
and vinculin (loading control) expression in MDA-436-PR and MDA-436-
DCXR cells 3 and 4 days post-infection with either shControl (Ctr) or shCIB1 
(CIB1). e) Paraptotic signaling in a chemo-resistant setting was analyzed 
by probing for IGF-1R, phosphor-JNK, total JNK, and Rac (loading control) 
in control or CIB1-depleted parental and docetaxel-resistant TNBC cells 
treated with either docetaxel (10 nM) or TRAIL (5 ng/mL) for 48 h (n=2).
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